The ALS Association has launched the ALS Focus Data Dashboard, a free interactive tool that gives researchers, clinicians, and the public access to five years of self-reported clinical, demographic, and socioeconomic data from more than 4,000 people with amyotrophic lateral sclerosis (ALS) and their caregivers across the U.S.

I wish I could shake the sadness I feel as my husband Todd’s caregiver after 15 years with ALS. There’s been a cloud over our lives since his diagnosis, even when his only physical symptom was a weak arm. Living with ALS has taken a toll on both…

Researchers in the U.S. and Europe have identified a number of novel blood and spinal fluid biomarkers that could help track amyotrophic lateral sclerosis (ALS) progression and monitor patient responses to therapeutic interventions, a new study reports. Several of the proteins found altered in people with ALS versus healthy…

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to CK0803, a regulatory T-cell therapy being developed by Cellenkos for amyotrophic lateral sclerosis (ALS), with a goal of slowing disease progression. The FDA designation is intended to accelerate the development and review of new treatments…

Amyotrophic lateral sclerosis (ALS) is more common in some parts of the U.S. than others, and it has a very strong geographic association with multiple sclerosis (MS), a new study suggests. The finding implies that some type of environmental factors may be increasing the risk of both…

Bristol Myers Squibb is extending a research collaboration with the artificial intelligence company Insitro to design new medicines against a novel target in amyotrophic lateral sclerosis (ALS). The target was identified during the previous five-year agreement between the companies, which aimed to discover new molecules that could…

People with amyotrophic lateral sclerosis (ALS) who also have diabetes tend to lose the ability to walk faster than non-diabetic patients, according to a study from Japan. The findings underscore the importance of supportive mobility care for diabetic ALS patients, scientists said in the study, “Factors…

EKZ-102, Eikonizo Therapeutics‘s experimental oral therapy for amyotrophic lateral sclerosis (ALS), is on track to enter early clinical testing in 2026, according to an announcement from the company. EKZ-102 is designed to block the activity of a protein called HDAC6. A team led by scientists at Eikonizo…

Last week, my husband, Todd, celebrated his 55th birthday — a milestone we never anticipated after he was diagnosed with ALS at age 39 in June 2010. For his 40th birthday that October, I asked friends and family to send me pictures and their favorite memories with Todd, and…

Once in a while, there’s a topic on the ALS News Today Forums that inspires a new column. The question posted was a simple one: “Do you celebrate ALS-related anniversaries?” I intended my reply to be just a simple “Yes.” But I ended up adding, “However, what I…